Latest BioPharma News and In-Depth Analysis

Innovent Biologics Announces Phase 3 Success for Mazdutide in Treating Type 2 Diabetes

Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of on...

July 22, 2024 | Monday | News

Shanghai Junshi Biosciences' sNDA for Toripalimab and Bevacizumab Combo for Advanced Liver Cancer Accepted by NMPA

Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializati...

July 19, 2024 | Friday | News

Merck Invests €6.6 Million to Expand Cell Culture Media Production at Nantong Site

€ 6.6 million investment at Nantong site expands production capabilities for cell culture media Supports local biopharma manufact...

July 16, 2024 | Tuesday | News

China's NMPA Approves First and Only Subcutaneous FcRn Blocker for gMG Patients

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigim...

July 16, 2024 | Tuesday | News

AusperBio Therapeutics Secures $37 Million Series A Financing

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to ...

July 15, 2024 | Monday | News

AHB-137 Receives Breakthrough Therapy Designation from NMPA, Paving the Way for Faster Access to Chronic Hepatitis B Treatment

AHB-137 gains Breakthrough Therapy Designation (BTD) from the NMPA based on Phase 1/Phase2a clinical trial data demonstrating safety and efficacy. BTD...

July 11, 2024 | Thursday | News

HUTCHMED's New aDrug Application for Tazemetostat in Relapsed or Refractory Follicular Lymphoma Granted Priority Review by China NMPA

HUTCHMED (China) Limited (“HUTCHMED”) announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of...

July 04, 2024 | Thursday | News

Junshi Biosciences' Toripalimab Approved in China for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of nov...

June 18, 2024 | Tuesday | News

AbbVie and FutureGen Announce Strategic Partnership to Develop Next-Generation IBD Therapy

AbbVie and FutureGen Biopharmaceutical (Beijing) Co., Ltd. announced a license agreement to develop FG-M701, a next generation TL1A antibody for th...

June 14, 2024 | Friday | News

Bio-Thera's Biosimilar Bevacizumab Avzivi® Receives Positive CHMP Opinion, Moves Closer to European Approval

Bio-Thera Solutions , a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, announced th...

June 05, 2024 | Wednesday | News

InnoCare Pharma Completes Patient Enrollment for Phase II Trial of ICP-488, Advancing Novel Psoriasis Treatment

InnoCare Pharma, a leading biopharmaceutical company dedicated to revolutionizing the treatment of cancer and autoimmune diseases, proudly announces ...

May 16, 2024 | Thursday | News

HUTCHMED Initiates Registrational Phase III Clinical Trial of HMPL-306 for Relapsed / Refractory Acute Myeloid Leukemia in China

AML, a challenging hematological malignancy, often involves mutations of IDH1 and IDH2 enzymes, necessitating innovative treatment strategies. HMPL...

May 14, 2024 | Tuesday | News

Photocure's Partner Asieris Pharmaceuticals Advances Cevira® for Potential Approval in China

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National...

May 13, 2024 | Monday | News

ArcScan's Insight® 100 Granted NMPA Approval in China, Offering Advanced Solution for Myopia Treatment

ArcScan, Inc., a global medical technology company dedicated to helping ophthalmologists improve vision with ultra-high frequency ultrasound diagnostic ima...